Madrigal is no longer a binary approval story. The company is a commercial MASH franchise trying to remain the backbone of care after Wegovy received a liver label last year. Rezdiffra still adds patients every quarter from a thinly diagnosed base. The investment debate is whether an oral, liver-directed pill keeps first-line share as incretins claim the same fibrosis stages.
The second-quarter print shows the launch is still compounding, not plateauing. Net product sales reached $364 million, up from the year-ago quarter. Active patients more than doubled versus last year. Cash and securities of $839 million fund the next wave of combination work. The income statement remains a loss because selling costs and two license checks still outrun gross profit.
The sequential add stayed in the mid thousands, and July crossed the 50000-patient mark. Three new resmetirom patents, including a method claim in compensated cirrhosis, extend Orange Book coverage deep into the next two decades. The question the next year resolves is whether those adds hold once Wegovy detailing overlaps the same fibrosis specialists.